Literature DB >> 21725921

Long-term effects of methylprednisolone pulses and mycophenolate mofetil in IgA nephropathy patients at risk of progression.

Dario Roccatello1, Daniela Rossi, Fabio Marletto, Carla Naretto, Savino Sciascia, Simone Baldovino, Doloretta Piras, Osvaldo Giachino.   

Abstract

BACKGROUND: IgA nephropathy (IgAN) is a microcosm of glomerular lesions. Some histologic lesions are irreversible and progress toward obliteration of glomerular capillaries. Others are acute inflammatory processes potentially susceptible to reversal by means of immunosuppressive therapies.
METHODS: The effects of a combined schedule of steroids and mycophenolate mofetil (MMF) was prospectively examined in a subset of IgAN patients with acute inflammatory histologic changes associated with proteinuria (mean 2,400 mg/day, range 1,130-5,250), hematuria (76 red cells per high-power microscopic field, range 30-100) and renal failure (serum creatinine 1.6 mg/dL, range 1.2-2.9). Patients had diffuse mesangial proliferation with at least 10% florid crescents, mild to moderate degrees of glomerular sclerosis and interstitial changes, and both mesangial and capillary deposition of immunoreactants at immunofluorescence. Treatment consisted of 3 pulses of methylprednisolone (15 mg/kg) followed by oral prednisone (0.8 mg/kg body weight, tapered until discontinuation within 4 months) and MMF 2 g for 6 months.
RESULTS: Serum creatinine, proteinuria and microscopic hematuria significantly dropped at 6 months compared with baseline values (p=0.01) and remained lower at the end of follow-up 51 months (range 24-90) later (p<0.01, for proteinuria and hematuria; p=0.08, for serum creatinine).
CONCLUSION: Therapy with steroids and MMF may be considered in a subset of IgAN patients with florid glomerular changes, functional impairment and major urinary abnormalities, to prevent subsequent progression toward renal failure.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21725921     DOI: 10.5301/JN.2011.8452

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  9 in total

1.  Update on immunoglobulin a nephropathy. Part II: Clinical, diagnostic and therapeutical aspects.

Authors:  Maurizio Salvadori; Giuseppina Rosso
Journal:  World J Nephrol       Date:  2016-01-06

Review 2.  The Treatment of IgA Nephropathy.

Authors:  Kar Neng Lai; Joseph C K Leung; Sydney C W Tang
Journal:  Kidney Dis (Basel)       Date:  2015-04-15

3.  Initial serum creatinine concentration affects clinical outcomes in patients with IgA nephropathy treated with mycophenolate mofetil combined with low-dose prednisone.

Authors:  Haiying Song; Haofei Hu; Fei Tang; Changchun Cao; Qijun Wan; Yongcheng He
Journal:  Exp Ther Med       Date:  2020-03-05       Impact factor: 2.447

Review 4.  Efficacy and safety of mycophenolate mofetil treatment in IgA nephropathy: a systematic review.

Authors:  Youyuan Chen; YuMin Li; ShengLin Yang; Yan Li; Min Liang
Journal:  BMC Nephrol       Date:  2014-12-05       Impact factor: 2.388

Review 5.  Primary glomerulonephritis: A review of important recent discoveries.

Authors:  Jürgen Floege
Journal:  Kidney Res Clin Pract       Date:  2013-07-26

6.  Corticosteroids and mycophenolic acid analogues in immunoglobulin A nephropathy with progressive decline in kidney function.

Authors:  Ana Huerta; Eva Mérida; Laura Medina; Maria Fernandez; Eduardo Gutierrez; Eduardo Hernandez; Paula López-Sánchez; Angel Sevillano; Jose Portolés; Hernan Trimarchi; Manuel Praga
Journal:  Clin Kidney J       Date:  2021-12-04

7.  A multicenter, randomized, open-label, comparative, phase IV study to evaluate the efficacy and safety of combined treatment with mycophenolate mofetil and corticosteroids in advanced immunoglobulin A nephropathy.

Authors:  Sang Youb Han; Chan-Young Jung; Sang Ho Lee; Dong Won Lee; Sik Lee; Chan-Duck Kim; Bum Soon Choi; Beom Seok Kim
Journal:  Kidney Res Clin Pract       Date:  2022-05-04

8.  Corticosteroids in patients with IgA nephropathy and severe chronic renal damage.

Authors:  Claudio Pozzi; Francesca Ferrario; Bianca Visciano; Lucia Del Vecchio
Journal:  Case Rep Nephrol       Date:  2012-10-10

9.  Efficacy and safety of mycophenolate mofetil in patients with IgA nephropathy: an update meta-analysis.

Authors:  Bing Du; Ye Jia; Wenhua Zhou; Xu Min; Lining Miao; Wenpeng Cui
Journal:  BMC Nephrol       Date:  2017-07-19       Impact factor: 2.388

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.